Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
| Autor: | Anurag Mehta, Rodney J. Scott, Wafaa El Metnawy, Gabriel de Souza Macedo, Pavel S. Borisov, Ravindran Kanesvaran |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
next generation sequencing medicine.medical_specialty medicine.diagnostic_test business.industry Genetic counseling Cancer Review Gene mutation medicine.disease Germline homologous recombination repair genetic testing Prostate cancer metastatic castration-resistant prostate cancer Internal medicine medicine Homologous recombination business Gene human activities Genetic testing |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | Patients with metastatic castration-resistant prostate cancer (mCRPC) have an average survival of only 13 months. Identification of novel predictive and actionable biomarkers in the homologous recombination repair (HRR) pathway in up to a quarter of patients with mCRPC has led to the approval of targeted therapies like poly-ADP ribose polymerase inhibitors (PARPi), with the potential to improve survival outcomes. The approval of PARPi has led to guideline bodies such as the National Comprehensive Cancer Network (NCCN) to actively recommend germline and or somatic HRR gene panel testing to identify patients who will benefit from PARPi. However, there are several challenges as genetic testing is still at an early stage especially in low- and middle-income countries, with cost and availability being major impediments. In addition, there are issues such as choice of optimal tissue for genetic testing, archival, storage, retrieval of tissue blocks, interpretation and classification of variants in the HRR pathway, and the need for pretest and post-test genetic counseling. This review provides insights into the HRR gene mutations prevalent in mCRPC and the challenges for a more widespread gene testing to identify actionable germline pathogenic variants and somatic mutations in the HRR pathway, and proposes a clinical algorithm to enhance the efficiency of the gene testing process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|